Drug Approval | April 26, 2022
Corbevax gets DCGI nod for Emergency Use in 5-12 years
The approval comes soon after Corbevax was given the nod for 12-15-year group
The approval comes soon after Corbevax was given the nod for 12-15-year group
Covaxin was earlier approved for children 12-18 years of age
Aflibercept is the second biosimilar product that has entered the clinical trial phase after biosimilar Adalimumab
Investment and innovation opportunities in the field of AYUSH are limitless : Sarbananda Sonowal
A separate global Phase 3 study of S-217622 is underway aiming to recruit participants globally to support regulatory filings this year
Desidustat is currently approved only in India as OxemiaTM for patients with CKD induced anemia
April 25th is commemorated as World Malaria Day
Deputy Mayor from Addis Ababa (Ethiopia) battled out a rare laryngeal cancer at Yashoda Hospitals Hyderabad
The commitment is expected to generate over 5.56 lakh jobs and positively impact the lives of more than 76 lakh people, the ministry said
If approved, Tecentriq will be the first and only cancer immunotherapy available for certain people with early-stage NSCLC in Europe
Subscribe To Our Newsletter & Stay Updated
